High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings

M. T. Lotze, A. E. Chang, C. A. Seipp, C. Simpson, John Vetto, S. A. Rosenberg

Research output: Contribution to journal › Article › peer-review

Fingerprint

Dive into the research topics of 'High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings'. Together they form a unique fingerprint.

Medicine & Life Sciences